CCL2/JE/MCP-1 Antibody (23007) [Unconjugated]

CCL2/JE/MCP‑1 was detected in immersion fixed paraffin-embedded sections of human Crohn's disease intestine using Mouse Anti-Human CCL2/JE/MCP‑1 Monoclonal Antibody (Catalog # MAB679) at 15 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell membranes and cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Recombinant Human CCL2/MCP‑1 (Catalog # 279-MC) chemoattracts the BaF3 mouse pro‑B cell line transfected with human CCR2A in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Human CCL2/MCP‑1 (75 ng/mL) is neutralized (green line) by increasing concentrations of Human CCL2/MCP‑1 Monoclonal Antibody (Catalog # MAB679). The ND50 is typically 0.5-2.0 µg/mL.

Expression patterns of CCL2, CCL5, TNF alpha and IL-1 beta in healthy individuals and breast cancer patients. Representative examples of the expression of CCL2, CCL5, TNF alpha and IL-1 beta in the different groups of patients included in the study, in biopsies obtained at the time of diagnosis. (a1-a4) Patients diagnosed with benign breast disorders. The pictures demonstrate the lack of staining of the four factors in the normal breast epithelial cells, as denoted in the majority of patients included in this group. (b1-b4) DCIS patients. The pictures demonstrate positive staining of the four factors in the malignant lesions, as denoted in the majority of patients included in this group. (c1-c4) IDC-no-relapse patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the majority of patients included in this group. (d1-d4) IDC-with-relapse patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the majority of patients included in this group. (a1, b1, c1, d1) CCL2 staining; (a2, b2, c2, d2) CCL5 staining; (a3, b3, c3, d3) TNF alpha staining; (a4, b4, c4, d4) IL-1 beta staining. The expression of the proteins was determined by IHC using specific antibodies, whose specificity in IHC was verified. The values of photo magnification are indicated in the left bottom corner of each of the pictures. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21486440), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression patterns of CCL2, CCL5, TNF alpha and IL-1 beta in healthy individuals and breast cancer patients. Representative examples of the expression of CCL2, CCL5, TNF alpha and IL-1 beta in the different groups of patients included in the study, in biopsies obtained at the time of diagnosis. (a1-a4) Patients diagnosed with benign breast disorders. The pictures demonstrate the lack of staining of the four factors in the normal breast epithelial cells, as denoted in the majority of patients included in this group. (b1-b4) DCIS patients. The pictures demonstrate positive staining of the four factors in the malignant lesions, as denoted in the majority of patients included in this group. (c1-c4) IDC-no-relapse patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the majority of patients included in this group. (d1-d4) IDC-with-relapse patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the majority of patients included in this group. (a1, b1, c1, d1) CCL2 staining; (a2, b2, c2, d2) CCL5 staining; (a3, b3, c3, d3) TNF alpha staining; (a4, b4, c4, d4) IL-1 beta staining. The expression of the proteins was determined by IHC using specific antibodies, whose specificity in IHC was verified. The values of photo magnification are indicated in the left bottom corner of each of the pictures. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21486440), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression patterns of CCL2, CCL5, TNF alpha and IL-1 beta in healthy individuals and breast cancer patients. Representative examples of the expression of CCL2, CCL5, TNF alpha and IL-1 beta in the different groups of patients included in the study, in biopsies obtained at the time of diagnosis. (a1-a4) Patients diagnosed with benign breast disorders. The pictures demonstrate the lack of staining of the four factors in the normal breast epithelial cells, as denoted in the majority of patients included in this group. (b1-b4) DCIS patients. The pictures demonstrate positive staining of the four factors in the malignant lesions, as denoted in the majority of patients included in this group. (c1-c4) IDC-no-relapse patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the majority of patients included in this group. (d1-d4) IDC-with-relapse patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the majority of patients included in this group. (a1, b1, c1, d1) CCL2 staining; (a2, b2, c2, d2) CCL5 staining; (a3, b3, c3, d3) TNF alpha staining; (a4, b4, c4, d4) IL-1 beta staining. The expression of the proteins was determined by IHC using specific antibodies, whose specificity in IHC was verified. The values of photo magnification are indicated in the left bottom corner of each of the pictures. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21486440), licensed under a CC-BY license. Not internally tested by R&D Systems.

Expression patterns of CCL2, CCL5, TNF alpha and IL-1 beta in healthy individuals and breast cancer patients. Representative examples of the expression of CCL2, CCL5, TNF alpha and IL-1 beta in the different groups of patients included in the study, in biopsies obtained at the time of diagnosis. (a1-a4) Patients diagnosed with benign breast disorders. The pictures demonstrate the lack of staining of the four factors in the normal breast epithelial cells, as denoted in the majority of patients included in this group. (b1-b4) DCIS patients. The pictures demonstrate positive staining of the four factors in the malignant lesions, as denoted in the majority of patients included in this group. (c1-c4) IDC-no-relapse patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the majority of patients included in this group. (d1-d4) IDC-with-relapse patients. The pictures demonstrate positive staining of the four factors in the tumor cells, as denoted in the majority of patients included in this group. (a1, b1, c1, d1) CCL2 staining; (a2, b2, c2, d2) CCL5 staining; (a3, b3, c3, d3) TNF alpha staining; (a4, b4, c4, d4) IL-1 beta staining. The expression of the proteins was determined by IHC using specific antibodies, whose specificity in IHC was verified. The values of photo magnification are indicated in the left bottom corner of each of the pictures. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/21486440), licensed under a CC-BY license. Not internally tested by R&D Systems.

Induction of CCL2 and CLXL8 in TNF alpha -stimulated MSCs is not mediated via the AP-1 pathway. (A) Human BM-derived MSCs were stimulated by TNF-alpha (50 ng/ml) for 5 and 10 minutes. Control cells were treated by the vehicle of TNF-alpha . c-Jun levels and phosphorylation were determined by western blot (WB) analyses. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control. (B) Human BM-derived MSCs were transiently transfected by small interfering RNA (siRNA) to c-Jun or by control siRNA. (B1) c-Jun expression was determined by WB analyses. beta -Tubulin was used as loading control. (B2) Following siRNA transfection, the cells were stimulated by TNF-alpha (25 ng/ml; in this part of the study we used a suboptimal concentration of TNF-alpha in order to facilitate detection of inhibitory effects) for 24 hours. Expression levels of CCL2 and CXCL8 in the supernatants of the cells were determined by ELISA, in the linear range of absorbance. #siRNA to c-Jun has yielded minor increases or reductions in CCL2 and CXCL8 secretion in different experiments (see Results and discussion), and thus overall there was no significant effect on CCL2 and CXCL8 secretion. In all panels, the findings are representatives of n = 3 independent experiments that have shown similar results. Image collected and cropped by CiteAb from the following publication (//stemcellres.biomedcentral.com/articles/10.1186/s13287-015-0080-7), licensed under a CC-BY license. Not internally tested by R&D Systems.

NF-kappa B is essential in mediating TNF-alpha -induced release of chemokines by MSCs. (A) Human BM-derived MSCs were stimulated by TNF-alpha (50 ng/ml) for 15 minutes. The levels of I kappa B alpha (the negative regulator of the NF-kappa B pathway) were determined by WB analyses. GAPDH was used as a loading control throughout. (B) CAFs were generated by culturing MSCs with Tumor CM from MDA-MB-231 (MDA) or MCF-7 breast tumor cells over a prolonged period of time (~30 days). TNF-alpha (50 ng/ml) was added for the last 24 hours to MSCs + Tumor CM cells and I kappa B alpha levels were determined by WB analyses. (C) CAF #1 cells were stimulated for 48 hours by TNF-alpha (50 ng/ml). I kappa B alpha levels were determined by WB analyses. (D) Human BM-derived MSCs were stimulated with TNF-alpha (50 ng/ml) for 10 minutes. p65 phosphorylation was determined by WB analyses. (E) Human BM-derived MSCs were transiently transfected by siRNA to p65 or by control siRNA. (E1) p65 expression was determined by WB analyses. (E2) Following siRNA transfection, the cells were stimulated by TNF-alpha (25 ng/ml; a suboptimal concentration of TNF-alpha in order to facilitate detection of inhibitory effects) for 48 hours. Expression of CCL2 and CXCL8 in the supernatants of the cells was determined by ELISA, in the linear range of absorbance. In all panels, the findings are representatives of n = 3 independent experiments that have shown similar results. Image collected and cropped by CiteAb from the following publication (//stemcellres.biomedcentral.com/articles/10.1186/s13287-015-0080-7), licensed under a CC-BY license. Not internally tested by R&D Systems.

Microparticle composition influences inflammatory cytokine production from activated monocytes.THP-1 cells (A) or CD14 sorted blood monocytes (B) were treated with control microparticles (grey bars) or PPAR gamma -overexpressing microparticles (black bars) or no microparticles (white bars) for 4 hours before activation with LPS or PAM3CSK4 for 24 hours. Supernatants were collected and pro-inflammatory cytokines IL-8 (top), MCP-1 (bottom) were measured by ELISA. Dotted line represents baseline cytokine production from unactivated cells with no microparticle exposure. Mean values with standard errors represent one of at least 3 experiments. Two-way ANOVA with Tukey's multiple comparison post test was performed to determine statistical significance. * indicates (pMAB679) at 20ug/mL with 1 hour incubation at room temperature followed by incubation with anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm and membrane.

• Reactivity: Hu
• Applications: WB, IHC, B/N, Dual ISH-IHC, ELISA(Cap)
• Clone: 23007
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

CCL2/JE/MCP-1 Antibody (23007) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CCL2/JE/MCP-1
• Specificity: Detects human CCL2/JE/MCP-1 in ELISAs and Western blots. In ELISAs, this antibody does not cross-react with recombinant mouse (rm) CCL2, 3, 4, rhCCL3, 4, 5, 7, or 8.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: CCL2
• Purity Statement: Protein A or G purified from ascites
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Dual RNAscope ISH-IHC 5-15 ug/mL
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 0.5-2.0 ug/mL
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Human CCL2/JE/MCP-1 Biotinylated Antibody (Catalog number BAF279)
  Standard: Recombinant Human CCL2/JE/MCP-1 (Catalog number 279-MC)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CCL2/JE/MCP-1 Antibody (23007) [Unconjugated]

• C-C motif chemokine ligand 2
• CCL2
• GDCF-2
• HC11
• HSMCR30
• MCAF
• Mcp1
• MCP-1
• SCYA2
• SMC-CF

Background

CCL2 is a beta -chemokine that is also known as monocyte chemotactic protein 1 (MCP-1). It is produced by a variety of cell types and is chemotactic for monocytes.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CCL2/JE/MCP-1 Antibody (MAB679)(50)

Publications using MAB679

• Sinclair, JE;Vedelago, C;Ryan, FJ;Carney, M;Redd, MA;Lynn, MA;Grubor-Bauk, B;Cao, Y;Henders, AK;Chew, KY;Gilroy, D;Greaves, K;Labzin, L;Ziser, L;Ronacher, K;Wallace, LM;Zhang, Y;Macauslane, K;Ellis, DJ;Rao, S;Burr, L;Bain, A;Karawita, A;Schulz, BL;Li, J;Lynn, DJ;Palpant, N;Wuethrich, A;Trau, M;Short, KR; Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function Nature microbiology 2024-10-30 [PMID: 39478108] (Bioassay, Human)
• Hong, J;Son, M;Sin, J;Kim, H;Chung, DK; Nanoparticles of Lactiplantibacillus plantarum K8 Reduce Staphylococcus aureus Respiratory Infection and Tumor Necrosis Factor Alpha- and Interferon Gamma-Induced Lung Inflammation Nutrients 2023-11-09 [PMID: 38004123] (ELISA Capture, Human)
• Brüser, L;Teichmann, E;Hinz, B; Effect of Flavonoids on MCP-1 Expression in Human Coronary Artery Endothelial Cells and Impact on MCP-1-Dependent Migration of Human Monocytes International journal of molecular sciences 2023-11-07 [PMID: 38003237] (Neutralization, Human)
• Kahm, YJ;Jung, U;Kim, RK; Regulation of Cancer Stem Cells and Epithelial-Mesenchymal Transition by CTNNAL1 in Lung Cancer and Glioblastoma Biomedicines 2023-05-17 [PMID: 37239133] (Neutralization, Human)
• Zhaoqiang Zhang, Zhongyu Xie, Jiajie Lin, Zehang Sun, Zhikun Li, Wenhui Yu et al. The m6A methyltransferase METTL16 negatively regulates MCP1 expression in mesenchymal stem cells during monocyte recruitment JCI Insight 2023-03-22 [PMID: 36795489] (Neutralization, Human)
• F Parween, SP Singh, HH Zhang, N Kathuria, FA Otaizo-Car, A Shamsaddin, PJ Gardina, S Ganesan, J Kabat, HA Lorenzi, TG Myers, JM Farber Chemokine positioning determines mutually exclusive roles for their receptors in extravasation of pathogenic human T cells bioRxiv : the preprint server for biology, 2023-02-13;0(0):. 2023-02-13 [PMID: 36789428] (ICC, Human)
• Lip Ket Chin, Jun-Yeong Yang, Benjamin Chousterman, Sunghoon Jung, Do-Geun Kim, Dong-Ho Kim et al. Dual-Enhanced Plasmonic Biosensing for Point-of-Care Sepsis Detection ACS Nano 2023-02-28 [PMID: 36745820]
• J Zhang, F Liu, Y Yang, N Yu, X Weng, Y Yang, Z Gong, S Huang, L Gan, S Sun, X Zhang, Y Gong, Y Liu, W Guo Integrated DNA and RNA sequencing reveals early drivers involved in metastasis of gastric cancer Cell Death & Disease, 2022-04-21;13(4):392. 2022-04-21 [PMID: 35449126] (Neutralization, Western Blot, Human)
• Lisha Luo, Shuanglinzi Deng, Wei Tang, Xinyue Hu, Feifei Yin, Huan Ge et al. Recruitment of IL‐1 beta ‐producing intermediate monocytes enhanced by C5a contributes to the development of malignant pleural effusion Thoracic Cancer 3/1/2022 [PMID: 35137541]
• L Wang, J Lan, J Tang, N Luo MCP-1 targeting: Shutting off an engine for tumor development Oncology Letters, 2021-11-19;23(1):26. 11/19/2021 [PMID: 34868363]
• Nikki P. L. Toledo, Hongzhao Li, Robert W. Omange, Tamara G. Dacoba, Jose Crecente-Campo, Dane Schalk et al. Cervico-Vaginal Inflammatory Cytokine and Chemokine Responses to Two Different SIV Immunogens Frontiers in Immunology 8/25/2020 [PMID: 32983121]
• S Abouelasra, M De Bondt, N Berghmans, M Gouwy, VLS de Oliveir, SC Oliveira, FA Amaral, P Proost, J Van Damme, S Struyf, M De Buck Biological Characterization of Commercial Recombinantly Expressed Immunomodulating Proteins Contaminated with Bacterial Products in the Year 2020: The SAA3 Case Mediators Inflamm., 2020-07-06;2020(0):6087109. 2020-07-06 [PMID: 32694927] (ELISA, Human)
• SW Wong, S Lenzini, MH Cooper, DJ Mooney, JW Shin Soft extracellular matrix enhances inflammatory activation of mesenchymal stromal cells to induce monocyte production and trafficking Sci Adv, 2020-04-08;6(15):eaaw0158. 2020-04-08 [PMID: 32284989] (Functional Assay, Human)
• Sara Abouelasrar Salama, Mieke Gouwy, Alexandra De Zutter, Noëmie Pörtner, Lotte Vanbrabant, Nele Berghmans et al. Induction of Chemokines by Hepatitis C Virus Proteins: Synergy of the Core Protein with Interleukin-1 beta and Interferon-gamma in Liver Bystander Cells Journal of Interferon & Cytokine Research 2020-04-01 [PMID: 32031878]
• D Ryan, J Koziol, WM ElShamy Targeting AXL and RAGE to prevent geminin overexpression-induced triple-negative breast cancer metastasis Sci Rep, 2019-12-16;9(1):19150. 12/16/2019 [PMID: 31844158]
• C Sun, X Li, E Guo, N Li, B Zhou, H Lu, J Huang, M Xia, W Shan, B Wang, K Li, D Weng, X Xu, Q Gao, S Wang, J Hu, Y Lu, GB Mills, G Chen MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis Oncogene, 2019-11-08;0(0):. 11/8/2019 [PMID: 31705064]
• Sally M. Salah, James D. Meisenheimer, Reena Rao, Jacqueline D. Peda, Darren P. Wallace, Dawson Foster et al. MCP-1 promotes detrimental cardiac physiology, pulmonary edema, and death in the cpk model of polycystic kidney disease American Journal of Physiology-Renal Physiology 2019-08-01 [PMID: 31091126]
• Kyoungrae Kim, Shihuan Kuang, Qifan Song, Timothy P. Gavin, Bruno T. Roseguini Impact of heat therapy on recovery after eccentric exercise in humans Journal of Applied Physiology 4/1/2019 [PMID: 30605396]
• HK Kim, SG Lee, SW Lee, BJ Oh, JH Kim, JA Kim, G Lee, JD Jang, YA Joe A Subset of Paracrine Factors as Efficient Biomarkers for Predicting Vascular Regenerative Efficacy of Mesenchymal Stromal/Stem Cells Stem Cells, 2018-10-08;0(0):. 2018-10-08 [PMID: 30281870]
• T Wang, Q Zhan, X Peng, Z Qiu, T Zhao CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel Oncol Lett, 2018-05-22;16(1):1267-1274. 2018-05-22 [PMID: 30061946] (Western Blot, Human)
• B Gril, AN Paranjape, S Woditschka, E Hua, EL Dolan, J Hanson, X Wu, W Kloc, E Izycka-Swi, R Duchnowska, R P?ksa, W Biernat, J Jassem, N Nayyar, PK Brastianos, OM Hall, CJ Peer, WD Figg, GT Pauly, C Robinson, S Difilippan, E Bialecki, P Metellus, JP Schneider, PS Steeg Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases Psychoneuroendocrinology, 2018-07-13;9(1):2705. 2018-07-13 [PMID: 30006619] (Neutralization, Human)
• Bing Liu, Lili Xu, Xinming Yu, Wei Li, Xiaozhi Sun, Shun Xiao, Mingjin Guo, Haofu Wang Protective effect of KLF15 on vascular endothelial dysfunction induced by TNF??. Molecular Medicine Reports, 2018-06-20;0(0):1791-3004. 2018-06-20 [PMID: 29956764] (Western Blot, Human)
• ZM Bian, MG Field, SG Elner, JM Kahlenberg, VM Elner Distinct CD40L receptors mediate inflammasome activation and secretion of IL-1? and MCP-1 in cultured human retinal pigment epithelial cells Exp. Eye Res., 2018-02-16;170(0):29-39. 2018-02-16 [PMID: 29454857] (Western Blot, Human)
• Y van Sleen, Q Wang, KSM van der Ge, J Westra, WH Abdulahad, P Heeringa, AMH Boots, E Brouwer Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis Sci Rep, 2017-07-26;7(1):6553. 2017-07-26 [PMID: 28747747] (IHC-P, Human)
• CM Henry, SJ Martin Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro-inflammatory FADDosome Complex upon TRAIL Stimulation Mol. Cell, 2017-02-16;65(4):715-729.e5. 2017-02-16 [PMID: 28212752] (ICC, Human)
• CCL2 as a potential therapeutic target for clear cell renal cell carcinoma Cancer Med, 2016-09-26;0(0):. 2016-09-26 [PMID: 27666332] (Neutralization, Mouse)
• Evidence for chemokine synergy during neutrophil migration in ARDS Thorax, 2016-08-05;0(0):. 2016-08-05 [PMID: 27496101] (Neutralization, Human)
• Association of MIF, but not type I interferon-induced chemokines, with increased disease activity in Asian patients with systemic lupus erythematosus Sci Rep, 2016-07-25;6(0):29909. 2016-07-25 [PMID: 27453287] (Human)
• Yi Li, Yuhuan Zheng, Tianshu Li, Qiang Wang, Jianfei Qian, Yong Lu et al. Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma Oncotarget 2015-09-15 [PMID: 26155942]
• Christina Katanov, Shalom Lerrer, Yulia Liubomirski, Leonor Leider-Trejo, Tsipi Meshel, Jair Bar et al. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-alpha and the NF-kappa B pathway Stem Cell Research & Therapy 2015-12-01 [PMID: 25928089]
• Sahler J, Woeller C, Phipps R Microparticles engineered to highly express peroxisome proliferator-activated receptor-gamma decreased inflammatory mediator production and increased adhesion of recipient monocytes. PLoS ONE, 2014-11-26;9(11):e113189. 2014-11-26 [PMID: 25426628] (ELISA Development (Capture), Human)
• Johanna Hol, Kari Otterdal, Unni M. Breland, Espen Stang, Turid M. Pedersen, Kathrine Hagelsteen et al. Statins Affect the Presentation of Endothelial Chemokines by Targeting to Multivesicular Bodies PLoS ONE 2012-07-16 [PMID: 22815786]
• Neveen Said, Marta Sanchez-Carbayo, Steven C. Smith, Dan Theodorescu RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration Journal of Clinical Investigation 2012-04-02 [PMID: 22406535]
• Kanno T, Kamba T, Yamasaki T et al. JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma. Oncogene. 10/24/2011 [PMID: 22020339]
• Xia Xi, David H. McMillan, Geniece M. Lehmann, Patricia J. Sime, Richard T. Libby, Krystel R. Huxlin et al. Ocular Fibroblast Diversity: Implications for Inflammation and Ocular Wound Healing Investigative Opthalmology & Visual Science 2011-07-01 [PMID: 21571679]
• Gali Soria, Maya Ofri-Shahak, Ilana Haas, Neora Yaal-Hahoshen, Leonor Leider-Trejo, Tal Leibovich-Rivkin et al. Inflammatory mediators in breast cancer: Coordinated expression of TNF alpha & IL-1 beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition BMC Cancer 2011-12-01 [PMID: 21486440]
• Schipper HS, De Jager W, van Dijk ME, Meerding J, Zelissen PM, Adan RA, Prakken BJ, Kalkhoven E A multiplex immunoassay for human adipokine profiling. Clin. Chem., 2010-06-08;56(0):1320. 2010-06-08 [PMID: 20530731] (Luminex Development, Human)
• Wu W, Mehta H, Chakrabarty K, Booth JL, Duggan ES, Patel KB, Ballard JD, Coggeshall KM, Metcalf JP Resistance of human alveolar macrophages to Bacillus anthracis lethal toxin. J. Immunol., 2009-10-07;183(9):5799-806. 2009-10-07 [PMID: 19812208] (ELISA Development, Human)
• Hu H, Kwun J, Aizenstein BD, Knechtle SJ Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation, 2009-06-27;87(12):1814-20. 2009-06-27 [PMID: 19543058] (Antibody Array Development, Human)
• Struyf S, Proost P, Vandercappellen J Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. Eur. J. Immunol., 2009-03-01;39(3):843-57. 2009-03-01 [PMID: 19224633] (ELISA Development, Human)
• Qui H, Ferrell EP, Nolan N, Phelps BH, Tabibiazar R, Whitney DH, Naelfski EA Fluorescence single-molecule counting assays for high-sensitivity detection of cytokines and chemokines. Clin. Chem., 2007-11-01;53(11):2010-2. 2007-11-01 [PMID: 18030696] (ELISA Development, Human)
• Pfleger C, Schloot N, ter Veld F Effect of serum content and diluent selection on assay sensitivity and signal intensity in multiplex bead-based immunoassays. J. Immunol. Methods, 2007-10-22;329(1):214-8. 2007-10-22 [PMID: 17964594] (Luminex Development, Human)
• Todd J, Freese B, Lu A, Held D, Morey J, Livingston R, Goix P Ultrasensitive flow-based immunoassays using single-molecule counting. Clin. Chem., 2007-09-21;53(11):1990-5. 2007-09-21 [PMID: 17890441] (ELISA Development, Human)
• Zhao Z, McCloud B, Fleming R, Klempner MS Borrelia burgdorferi-induced monocyte chemoattractant protein-1 production in vivo and in vitro. Biochem. Biophys. Res. Commun., 2007-05-02;358(2):528-33. 2007-05-02 [PMID: 17485071] (Neutralization, Human)
• Otterdal K, Smith C, Oie E, Pedersen TM, Yndestad A, Stang E, Endresen K, Solum NO, Aukrust P, Damas JK Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood, 2006-08-01;108(3):928-35. 2006-08-01 [PMID: 16861346] (ELISA Development, Human)
• Rubina W. Saeed, Santosh Varma, Tina Peng-Nemeroff, Barbara Sherry, David Balakhaneh, Jared Huston et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation The Journal of Experimental Medicine 2005-04-04 [PMID: 15809354]
• Mozaffarian D, Rimm EB, King IB, Lawler RL, McDonald GB, Levy WC trans fatty acids and systemic inflammation in heart failure. Am. J. Clin. Nutr., 2004-12-01;80(6):1521-5. 2004-12-01 [PMID: 15585763] (ELISA Development, Human)
• Eugenin EA, Dyer G, Calderon TM, Berman JW HIV-1 tat protein induces a migratory phenotype in human fetal microglia by a CCL2 (MCP-1)-dependent mechanism: possible role in NeuroAIDS. Glia, 2005-03-01;49(4):501-10. 2005-03-01 [PMID: 15578658] (Neutralization, Human)
• Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc. Res., 2004-09-01;63(4):617-24. 2004-09-01 [PMID: 15306217] (Western Blot, Porcine)
• Oynebraten I, Bakke O, Brandtzaeg P, Johansen FE, Haraldsen G Rapid chemokine secretion from endothelial cells originates from 2 distinct compartments. Blood, 2004-03-25;104(2):314-20. 2004-03-25 [PMID: 15044249] (ICC, Human)

Bioinformatics

• Gene Symbol: CCL2